Berndt Modig, Pharvaris CEO

Phar­varis hits a snag with hered­i­tary an­gioede­ma pill as FDA places hold on tri­als

Swiss biotech Phar­varis an­nounced Mon­day that the FDA has placed a hold on the clin­i­cal tri­als for its oral drug PHA121 which aims at treat­ing hered­i­tary an­gioede­ma, or HAE, a rare ge­net­ic con­di­tion.

The reg­u­la­tors placed the hold af­ter re­view­ing the com­pa­ny’s non­clin­i­cal da­ta, Phar­varis said. The FDA’s de­ci­sion is a set­back for the com­pa­ny’s Phase II study, which aims to eval­u­ate the ef­fi­ca­cy and safe­ty of the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.